AKTX

Akari Therapeutics Plc AKTX

NasdaqMega CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.6M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$1.54M total
MMCAP International Inc. SPC
$1.02MNew
Cresset Asset Management, LLC
$210.6K0.0%
JANE STREET GROUP, LLC
$158.4KNew
HRT FINANCIAL LP
$140.0KNew
IFP Advisors, Inc
$1.9K-97.6%
SBI Securities Co., Ltd.
$143+180.0%
Caitong International Asset Management Co., Ltd
$82New
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
$72New
Truvestments Capital LLC
$100.0%
See all 9 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/AKTX

Earnings Per Share

13fpro.ai/company/AKTX

Loading ratio trend…

AKTX key financials by period

Reported revenue, net income and operating margin by fiscal year, from Akari Therapeutics Plc's annual filings on SEC EDGAR.

Akari Therapeutics Plc reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2023$367.9K$-10.0M—
FY 2022$607.7K$-17.7M—
Source: AKTX filings on SEC EDGAR →

AKTX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Akari Therapeutics Plc (AKTX): stock profile, AI score and financials

Akari Therapeutics Plc (AKTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. AKTX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.6m in revenue and is scored on the micro-cap board instead. Top institutional holders of AKTX by reported 13-F value include MMCAP International SPC, Cresset Asset Management, JANE STREET GROUP, based on the most recent SEC filings. AKTX trades on the Nasdaq exchange and files with the SEC under CIK 1541157. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AKTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Akari Therapeutics Plc directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1541157 →